

Binswanger's Disease And Neurocysticercosis

H Foyaca-Sibat, L Ibañez-Valdés

Citation

H Foyaca-Sibat, L Ibañez-Valdés. *Binswanger's Disease And Neurocysticercosis*. The Internet Journal of Neurology. 2002 Volume 2 Number 1.

Abstract

We report seven patients who presented with clinical manifestations of ischemic cerebrovascular disease (CVD), dementia, and on CT Scan radiological signs of active neurocysticercosis and Binswanger's Disease (BD) were found. Two patients died due to bilateral pulmonary thromboembolism secondary to deep venous thrombosis on lower limbs and the others remain alive. In almost all of them after one day of treatment with praziquantel (PZQ) some aggravation of the clinical manifestations of BD were observed. We have hypothesized about the *Taenia solium*-microglial activation-coagulation disorder and glial disorders-Blood-Brain-Barrier disturbances-Binswanger's disease. We considered that anti-parasitic therapy for active NCC in patients with an associated BD should not be prescribed except for isolated cases when it's extremely necessary.

INTRODUCTION

In 1550, neurocysticercosis (NCC) is described for the first time when Parandi found some rounded vesicles filled of cerebrospinal fluid (CSF) on the corpus callosum in a patient with cerebrovascular disease (CVD). In 1558 Kumber provided a more detailed description of NCC from the autopsy of epileptic patient and Malpighi in 1686 nominated it as a parasitic disease and identified the parasites into the intracerebral vesicles which were named cysticercus by Laennec in XIX century.¹ NCC is the most common parasitic infection of the brain caused by the larval stage (cysticercus cellulosae) of the pig tapeworm *Taenia solium*, affecting more than 50 million of peoples all over the world. NCC is characterized by epilepsy, intracranial hypertension, neuropsychiatry manifestation, dermatological and ocular problems, more detailed information about NCC in our region are available on-line.^{2 3 4 5}

In 1672, the English physician Thomas Willis (1621-1672) provides the first accurate clinical observations of patients with post-stroke vascular dementia. Willis said: "I have observed in many cases that when, the Brain being indisposed, they have been distemper'd with a dullness of mind and forgetfulness, and then afterwards with a stupidity and foolishness, they would afterwards have fallen into a Palsie, which I oft did predict. For according as the places obstructed are more or less large so either a universal Palsies, or an half Palsie of one side, or else some partial resolutions of members happen".⁶

In 1938, Dechambre described lacunes for the first time while worked under Cruveilhier supervision at the Salpêtrière Hospital in France. The word lacune (French lacune from the Latin lacuna, ae, a tiny hole, pit, or cavity) denotes a small, cystic cavity of the brain substance that usually results from an ischemic infarction in the territory of a penetrating arteriole; lacunes may follow very rarely small deep hemorrhages or an isolated giant dilation of the perivascular space.⁶

In 1894, Alzheimer and Binswanger described "arteriosclerotic brain atrophy", a condition characterized by "military apoplexies" or "disease foci" (lacunar infarcts) affecting the basal ganglia, internal capsule, and white matter (WM) of the Centrum ovale, associated with severe arteriosclerosis of small and large vessels.⁶ he also described an associated enlarged ventricles and normal cerebral cortex, Binswanger separated it from neurosyphilis and other forms of dementia in elderly peoples.⁷

The term état criblé (Cribiform state) and leucoaraiosis described in 1842 and 1987 respectively refers to the dilations of perivascular spaces around cerebral arterioles in the brain of elderly peoples and the radiological images of loss of density of the periventricular WM observed by computerized tomography (CT) of the brain accordingly.

In some textbook of neurology, Binswanger's disease (BD) is described as a very uncommon disorder characterized by pseudobulbar palsy with vascular dementia due to lesions on the WM, and leucoaraiosis (LA) is seen on the CT Scan or

MRI in third age's patients (sixth or seventh decade). To the knowledge of those authors, about 150 cases had been reported,⁷

The attenuation of the subcortical GM (LA) is a hallmark of the BD. When this syndrome was described by Binswanger, he identified it as a different form of dementia (encephalitis subcorticalis chronica) with lesions of the subcortical WM "severe atheromatosis of the arteries." In 1982 Tomonaga⁸ reported an incidence of BD between 3 to 12 percent in the elderly. The etiology of BD is still not certain but dysfunction of the blood-brain-barrier seems to be always present.

Some of the pathological hallmark (WM lesions) of BD are also present in NCC. We have been investigated patients with NCC and associated ischemic cerebrovascular disease (CVD), but unfortunately at the present moment that information is still in process, however lesions of the WM in ischemic stroke does not differ from lesions on the WM in BD (WM lesions plus lacunes) although that lesions are more diffuse and prominent in BD.⁹

The aim of this study is to report our finding in some patients with clinical criteria of BD such as: dementia, bilateral radiological abnormalities on computer tomography, evidence of systemic vascular disease, and evidence of focal CVD or evidence of "subcortical cerebral dysfunction"¹⁰ and the international accepted criteria for NCC such as evidence of cystic lesion showing the scolex on the CT Scan of the brain.

MATERIAL AND METHODS

Seven patients fulfilling the clinical criteria of BD and the absolute criteria for NCC were identified prospectively for the study among patients referred to neurology clinic in Umtata General Hospital from peripheral primary-care hospital and health centers during five years period. Some of those patients presented with an associated pulmonary tuberculosis (PTB) and all of them with long-standing history of arterial hypertension. Hypertension was diagnosed according to the criteria of the World Health Organization (Geneva, Switzerland; 1985. Technical Report Series 727). Our hospital is a secondary-care institution, serving a rural area of about 6, 4 million peoples. Patients with stroke (defined as focal neurological deficits of acute onset, lasting more than 24 hours, due to brain ischemia as shown by CT Scan or after clinical and neuroradiological workup) were admitted to our Stroke Units (female and male) after examination in the emergency and casualty department,

without further selection. Those patients were studied according to the following protocol: Detailed history of the present complaint, identification of the risk factors for stroke, and physical examination, neurological evaluation at entry and daily for the first ten days, laboratory tests, chest x-ray, electrocardiogram and hemodynamic tests, CT Scan of the brain, coagulation screen, lipid profile, and others looking for cardiovascular diseases or peripheral vasculopathies were carried out when necessary.

After the CT scan of the brain, eligible patients (n=7) had an active form of NCC without clinical signs of raised intracranial pressure or epilepsy.

Exclusion criteria for anti-parasitic treatment in this group included age < 59 or > 81 years, resolution of deficits within 24 hours, normal CT Scan, history of alcohol abuse (ie, > 600 g/wk), history of retarded psychomotor development, psychosis, other CNS disorder or systemic diseases known to involve the CNS, patients with severe aphasia and/or sensory impairment (blindness, deafness), severe depression and finally high suspicion of tuberculomas, pyogenic brain abscesses, mycotic granulomas, and primary or metastatic brain tumors (See the flow chart). Apart from aspirin and anticoagulant (when it was necessary), steroids medications and antiparasite treatment, other concomitant treatment was prohibited for patient while participating in the study. All patients received 100mg/kg of PZQ divided in four oral dosages of 25mg/kg each for one day only and 30 mg of prednisone daily during 4 consecutive days, and 150 mg of aspirin after breakfast. We obtained informed consent from each patient.

OUTCOME MEASURES

Response to anti-parasite treatment were assessed by neurological evaluation of the CVD disease manifestation at the baseline and one week after the anti-parasitic treatment with PZQ and also with CT Scan of the brain the treatment (a week after) All patient received the same supporting treatment and were encouraged to eat a rich carbohydrate meals and all were evaluated throughout the study by the same personnel.


RESULTS

An experienced neurologist evaluated all patients, none patients had no previous history of any other neurological disease apart from clinical manifestations of CVD. All patients presented with elevated systolic and diastolic blood pressure ranged from 146/93mmHG to 169/114 mmHg.

(Table I).

Figure 1


Table 1



Although cognitive disorder and urinary incontinence are common clinical signs in this group; however combination of memory dysfunction, difficulty walking, and stroke in all of them were observed. (Table II).

Figure 2

Table 2



Absolute criteria for NCC based on neuroimaging findings were present in all selected patients considering the cystic lesion with scolex (bright nodule within the cyst, producing the so-called “hole-with-dot” imaging) as patognomonic (Figure 1), leukoaraiosis was present in all patients, and lacunar infarct on the basal ganglia in six of them (Table III).

Figure 3

Figure 1: CT Brain Scan showing active NCC (left) and lacunar infarction on the head of the caudate nucleus (right) and lecoaraiosis





Figure 4

Table 3



On physical examination one patient evidenced a mild improvement of gait after one single day therapy with praziquantel, one remained without remarkable changes and the others five worsened. (Table IV) One patient developed generalized tonic-clonic epileptic attacks, other 2 died after coagulation disorders complications and presented deep venous thrombosis, massive pulmonary embolism, and ischemic hemorrhagic stroke (Figure 2) and microglial activation (Figure 3) the others evidenced faster deterioration of the cognitive dysfunction and memory.

Figure 5

Table 4




Figure 6

Figure 2: Thromboembolism and focal micro-haemorrhage (15PM02, H/E. 10X)





Figure 7


Figure 3: Microglial activation



Efficacy analysis included 7 patients (4 women and 3 man, mean age 65,17, years, range 60 to 71) treated with praziquantel/prednisone. Patients with poorest prognosis showed signs of chronic arterial hypertension such as “onion-skin” changes in renal blood vessels (Figure 4)

Figure 8

Figure 4: “Onion Skin” change in renal blood vessel (15PM02, HE 20X)



COMMENTS

From our personal experience BD is more common than the figure described by Gautier,⁷ and is characterized among other signs by subcortical neurological deficits such as gait abnormalities, rigidity, and neurogenic bladder plus psychiatry disorders including mood changes and depression, loss of memory and cognition, hypertension, evidence of systemic vascular disease or disease of the large blood vessels in the neck, stroke, blood abnormalities, and disease of the heart valves in people oldest than 60 years.

To treat patients with NCC medically is still a controversial

problem; ¹² more than two millions of biomedical articles are published every year, and after review of some of them we also found no evidence for treat all patients with NCC or insufficient evidence to assess whether cysticidal therapy in NCC is associated with beneficial effects (2002 Cochrane Database of Systematic Reviews)¹³ in some articles we found small population for the study, no randomization and double blindness, no control group, no adequate outcome measuring, wrong statistical analysis, no inclusion or exclusion criteria, poor discussion of the results and some bioethical problems.^{14 15 16 17 18 19} In spite of the above-mentioned mistakes on research planning, we personally believe that some symptomatic patients without other associated neurological complication require anti-cysticidal therapy for NCC.

Ischaemic CVD is a relatively common but under-recognized complication of NCC usually caused by inflammatory occlusion of the arteries at the base of the brain secondary to cysticercotic arachnoiditis, and lacunar and large infarcts have been reported.²⁰ Two of our patients die soon after treatment with PZQ for active lesions of NCC in vesicular stage, both developed ischemic CVD and microhemorrhage (found on the necropsy); in one patient a remarkable deep venous thrombosis which did not respond to heparine intravenously was confirmed. Cerebral infarction has been reported ^{21 22} but not in BD type, therefore from our knowledge it is a novel association not previously reported in the medical literature. Seizure disorder as complication of praziquantel therapy has been also reported,²³ in spite of the limitations to differentiated seizures secondary to NCC or PZQ we believe that seizures in our series are NCC related rather than side effect of praziquantel because NCC is the most common cause of acquired epilepsy worldwide and because we have been treating thousands patients with praziquantel for a long time and never ever found similar complication in non-epileptic patients. However seizures also can be present as part of the clinical feature of BD. Why those complications happened after praziquantel therapy? Well, some neurophysiopathological events present when that parasite is dying can explain some aspects. Why aggravation of cognitive dysfunction after praziquantel? First of all is good to establish that we could not distinguish patients with vascular dementia (cognitive syndrome of vascular cause) due to BD from patients with dementia due to Alzheimer Disease (AD) being it a handicap for any credible theoretical explanation but hallmark of BD is WM lesion which can be characterized by lacunes (small infarction less than 1.5 cm in diameter in a deep location

without evidence of significant heart disease), *état criblé* (cribiform or sieve-like atrophy), brain interstitial atrophy, *état lacunaire*, and *encephalitis subcorticalis chronica progressiva* (Binswanger's), and "unidentified bright objects" (UBOs) on the MRI.

Those lesion with hyperintensity in the periventricular WM are zones of chronic WM ischemia due to microvascular disease in the terminal zones of the medullary arteries, typically sparing the short, arcuate subcortical fibers in a pattern that has become associated with BD (partial loss of myelin sheaths and oligodendroglial cells and axon, producing a decrease of the meshwork of the WM tissue, along with mild reactive fibrillary gliosis and sparse macrophages.²⁴ those lesions can be involved in the mechanism of aggravation of cognitive functions mainly after toxins-released by the dying cysticercus, however because some of this finding can be seen also on the brain of elderly peoples and patient with AD we are not considering such pathological changes as pathognomonic of BD in our series. It is generally well known that senile dementia of the Binswanger type is a well-defined medical condition more commonly diagnosed in centers where technique for myelin stain are used.

Although the role of alterations of the blood-brain-barrier linked to hypertensive episodes with chronic vasogenic edema in patients with BD is not well-defined, the role of platelet activation as a major participant in the etiology of thromboembolic stroke is well known. Thromboglobulin (BTG) is a platelet-specific protein that is released into the circulation from activated platelets, its concentration is an indicator of platelet activation in the systemic circulation and its concentration can be influenced by the presence of atherothrombotic lesions, arrhythmias, aging, renal functional impairment,²⁵ and probable vascular lesion associated to cysticercosis. BD promote platelet-derived substances released reactions, inducing vessel wall damage and causing neuronal impairment downstream, chronic ischemia in the hemispheric white matter based on the same mechanism that is aggravated in patients with NCC when the parasite is dying due to host's immunological attack or by anti-cysticidal drugs.

After reviewed the South Africa Literature about NCC^{26 27 28 29 30} after considering that cerebrovascular diseases are the second common cause of dementia, knowing that cerebrovascular disease is one of the complications of NCC, and that ischemic stroke during praziquantel therapy due to a

secondary inflammatory vascular reaction in neurocysticercosis has been reported,^{31 32 33} we finally considerate that there is insufficient evidence to determine whether cysticidal therapy is of any clinical benefit to patients with neurocysticercosis and agree with Salinas' article,³⁴ therefore we concluded that anti-parasitic medication against *Taenia solium* for patients with NCC and an associated BD, is not indicated until proven otherwise. We suggest a more emphasis in better primary health care system and health education, vaccination of the pig population, better sanitation and alleviation of poverty as a better way for solving this problem.

References

1. Hernandez-Cossio O, Hernandez O. Neurocysticercosis y epilepsia en Cuba. *Rev Neurol* 1999;29:1003-1006.
2. Foyaca-Sibat H, Ibañez-Valdés L de F, Awotedu A, Fernandez-Mena C. The Third International Congress of Critical Care Medicine on Internet. Nov. 2001. <http://www.uninet.edu/cimc2001/comunicaciones/foyaca/index.html>
3. Foyaca-Sibat H, Ibañez-Valdés L de F, Awotedu A, Fernandez-Mena C. Neurocysticercosis in the Former Transkei. 7th Internet World Congress for Biomedical Sciences. Inabis 2002. April 14-20, 2002. Available on-line at: <http://www.inabis2002.org/poster-congress.area-01/01011/010117.pdf>
4. Foyaca-Sibat H, Ibañez-Valdés L de F. Clinical Trial of praziquantel and prednisone in rural patients with recurrent epileptic attacks. *The Internet Journal of Neurology* 2002;I(2):8-17 available on-line at: <http://www.ispub.com/ostia/index.php?xmlFilePath=Journal/s/ijn/vol1n2/ncc.xml>
5. Foyaca-Sibat H. Tapeworm and the Brain. *Science in Africa*. 2002 June XVIII. <http://www.scienceinAfrica.co.za/2002/june/worm.htm>
6. Román CR. On the History of Lacunes, Etat criblé, and the White Matter Lesions of Vascular Dementia. *Cerebrovasc Dis* 2002;13(suppl 2):1-6.
7. Gautier JC, Mohr JP. Ischemic Stroke. *Binswanger's Disease. Guide to clinical neurology*. Churchill Livingstone ED 1995 pag 563-564.
8. Tomonaga M, Yamanouchi H, Tohgi H, Kameya M. Clinicopathologic study of progressive subcortical vascular encephalopathy (Binswanger type) in the elderly. *J Am Geriatr Soc* 1982;30:521-529.
9. Akiguchi I, Tomimoto H, Suenaga T, Wakita H, Bugka H. Alterations in Glia and Axons in the Brains of Binswanger's Disease Patients. *Stroke* 1997;28:1423-1429.
10. Bennett DA, Wilson RS, Gilley DW, Fox JH. Clinical diagnosis of Binswanger's disease. *J Neurol Neurosurg Psych* 1990(3):961-965.
11. Del Brutto, Rajshekhkar V, White Jr AC, Tsang VCW, et al. Proposed diagnostic criteria for neurocysticercosis. *Neurology* 2001;57:177-183.
12. Salinas R, Counsell C, Prasad K, Gelband H, Garnet P. Treating neurocysticercosis medically: a review of randomized, controlled trials. *Trop Med Int Health* 1999; 4(11):13-18.
13. Salinas R, Prasad K. Drugs for treating neurocysticercosis (tapeworm infection of the brain). *Cochrane Database of Systematic Reviews*. Issue 2, 2002.
14. Chotmonkol V. Treatment of neurocysticercosis with a two week course of albendazole. *Southeast Asian J Trop Med Pub Health*. 1993;24(2):396-398.
15. Sotelo J, Flisser A. Neurocysticercosis. *Practical Treatment guidelines. Cns Drugs* 1997;7(1):17-25.
16. Garcia HH, Gilman RH, Horton J, Martinez M, Herrera G, Altamirano J, Cuba JM, Rios-Saavedra N, Verastegui M, Boero J, Gonzalez AE. Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. *Neurology* 1997;48(5):1421-1427.
17. Sotelo J, Jung H. Pharmacokinetic optimization of the treatment of neurocysticercosis. *Review* 1998;34(6):503-515.
18. Del Brutto OH, Campos X, Sanchez J, Mosquera A. Single-day praziquantel versus 1-week albendazole for neurocysticercosis. *Neurology* 1999;52(5):1079-1081.
19. Singhi P, Ray Singhi S, Khandelwal N. Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. *J Child Neurol*. 2000;15(4) : 207-213.
20. Del Brutto OH. Cysticercosis and cerebrovascular disease: a review. *J Neurol Neurosurg Psy* 1992;55:252-254.
21. Young Bang Oh, Hoe HJ, Choi SA, Kim DI. Large cerebral infarction during praziquantel therapy in neurocysticercosis. *Stroke* 1997;28:211-213.
22. Woo E, Yu YL, Huang CY. Cerebral infarction precipitated by praziquantel in neurocysticercosis: a cautionary note. *Trop Geogr Med*. 1988;40:143-146.
23. Fong GCY, Cheung RTF. Caution with praziquantel in neurocysticercosis. *Stroke* 1997;28:1648-1649.
24. Roman C.G. Impact of Magnetic Resonance Imaging on Vascular Dementia Research. *Stroke* 1996;27:1269-1273.
25. Iwamoto T, Kubo H, Takasaki M. Platelet Activation in the Cerebral Circulation in Different Subtypes of Ischemic Stroke and Binswanger's Disease. *Stroke* 1995;26:52-56.
26. Joubert J, Joubert MJ, Lombaard CM. Neurocysticercosis, a comprehensive approach to medical treatment. *S Afri Med J*. 1985;63:11-14.
27. Shasha W, van Dellen J, Cakata E. Cysticercosis: an analysis of 141 cases in South Africa. *S. Afri J Epidem. Infect.* 1986;1:94-97.
28. Joubert J, and van As Ad. Rapid resolution of giant cysticercal cysts after administration of praziquantel: a report of 4 cases. *S. Afri Med J*. 1990;77:154-157.
29. Thomson AJ. Neurocysticercosis, experience at the teaching hospital of the University of Cape Town. *S Afri Med J*. 1993;83:332-334.
30. Bhigjee AI, Sanyika C. Disseminated cysticercosis. *J Neurol Neurosurg Psychiatry* 1999;66:545-546.
31. Woo E, Yu YL, Huang CY. Cerebral infarction precipitated by praziquantel in neurocysticercosis: a cautionary note. *Trop Geogr Med*. 1988;40:143-146.
32. Bang OY, Heo JH, Choi SA, Kim DI. Large cerebral infarction during praziquantel therapy in neurocysticercosis. *Stroke*. 1997;28:211-213.
33. Del Brutto OH, Sotelo J, Roman GC. Therapy for neurocysticercosis: a reappraisal. *Clin Infect Dis*. 1993;17:730-735.
34. Salinas R, Counsell C, Prasad K, Gelband H, Garnet P. Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. *Trop Med Int Health*. 1999;4(11):713-718.

Author Information

H. Foyaca-Sibat

Department of Neurology , University of Transkei

LdeF Ibañez-Valdés

Department of Family Medicine, University of Transkei